Tumour tissue: Who is in control?

Martine Corrette Ploem; Valesca P. Retèl; Sabine C. Linn; Hester H. van Boven; Marjanka K. Schmidt; Jean Philippe de Jong; Joseph K.M. Gevers; Wim H. van Harten

doi:10.1016/S1470-2045(09)70318-3

Tumour tissue: Who is in control?

Martine Corrette Ploem, Valesca P. Retèl, Sabine C. Linn, Hester H. van Boven, Marjanka K. Schmidt, Jean Philippe de Jong, Joseph K.M. Gevers, Wim H. van Harten (Corresponding Author)

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

6 Downloads (Pure)

Abstract

Recent developments in genomics have resulted in the increased availability of gene profiles for early diagnosis and prognosis in breast cancer. A request from a Dutch woman to have her tumour tissue tested years after treatment confronted the Netherlands Cancer Institute (NKI) and its staff with legal, ethical, and practical questions regarding patients' rights in relation to residual tissue storage and its use for clinical purposes. Was her tissue still available? If so, could she demand that the test be carried out or her tissue be transferred to another hospital? As it became apparent that appropriate guidance was lacking in this area, we developed guidelines on the issue, with the involvement of relevant professionals and patient representatives within the framework of a Technology Assessment project.1

Gene-expression profiling is an important development that is likely to predict the diagnosis and prognosis of malignant disease more accurately than existing clinicopathological parameters.2 Although gene-expression profiling is not yet routine, several tests are already applied in clinical practice. Additionally, the 70-gene signature (MammaPrint), which uses microarrays on fresh frozen tumour tissue, is being tested in a multicentre randomised trial (MINDACT).3 However, for such tests to be successful it is essential that sufficient tumour tissue is available.

Original language	English
Pages (from-to)	9-11
Journal	Lancet oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(09)70318-3
Publication status	Published - 2010

Keywords

n/a OA procedure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(09)70318-3

Cite this

@article{0d180f41ab04425ba1bfbccab64ede42,

title = "Tumour tissue: Who is in control?",

abstract = "Recent developments in genomics have resulted in the increased availability of gene profiles for early diagnosis and prognosis in breast cancer. A request from a Dutch woman to have her tumour tissue tested years after treatment confronted the Netherlands Cancer Institute (NKI) and its staff with legal, ethical, and practical questions regarding patients' rights in relation to residual tissue storage and its use for clinical purposes. Was her tissue still available? If so, could she demand that the test be carried out or her tissue be transferred to another hospital? As it became apparent that appropriate guidance was lacking in this area, we developed guidelines on the issue, with the involvement of relevant professionals and patient representatives within the framework of a Technology Assessment project.1Gene-expression profiling is an important development that is likely to predict the diagnosis and prognosis of malignant disease more accurately than existing clinicopathological parameters.2 Although gene-expression profiling is not yet routine, several tests are already applied in clinical practice. Additionally, the 70-gene signature (MammaPrint), which uses microarrays on fresh frozen tumour tissue, is being tested in a multicentre randomised trial (MINDACT).3 However, for such tests to be successful it is essential that sufficient tumour tissue is available.",

keywords = "n/a OA procedure",

author = "Ploem, {Martine Corrette} and Ret{\`e}l, {Valesca P.} and Linn, {Sabine C.} and {van Boven}, {Hester H.} and Schmidt, {Marjanka K.} and {de Jong}, {Jean Philippe} and Gevers, {Joseph K.M.} and {van Harten}, {Wim H.}",

year = "2010",

doi = "10.1016/S1470-2045(09)70318-3",

language = "English",

volume = "11",

pages = "9--11",

journal = "Lancet oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "1",

}

TY - JOUR

T1 - Tumour tissue

T2 - Who is in control?

AU - Ploem, Martine Corrette

AU - Retèl, Valesca P.

AU - Linn, Sabine C.

AU - van Boven, Hester H.

AU - Schmidt, Marjanka K.

AU - de Jong, Jean Philippe

AU - Gevers, Joseph K.M.

AU - van Harten, Wim H.

PY - 2010

Y1 - 2010

N2 - Recent developments in genomics have resulted in the increased availability of gene profiles for early diagnosis and prognosis in breast cancer. A request from a Dutch woman to have her tumour tissue tested years after treatment confronted the Netherlands Cancer Institute (NKI) and its staff with legal, ethical, and practical questions regarding patients' rights in relation to residual tissue storage and its use for clinical purposes. Was her tissue still available? If so, could she demand that the test be carried out or her tissue be transferred to another hospital? As it became apparent that appropriate guidance was lacking in this area, we developed guidelines on the issue, with the involvement of relevant professionals and patient representatives within the framework of a Technology Assessment project.1Gene-expression profiling is an important development that is likely to predict the diagnosis and prognosis of malignant disease more accurately than existing clinicopathological parameters.2 Although gene-expression profiling is not yet routine, several tests are already applied in clinical practice. Additionally, the 70-gene signature (MammaPrint), which uses microarrays on fresh frozen tumour tissue, is being tested in a multicentre randomised trial (MINDACT).3 However, for such tests to be successful it is essential that sufficient tumour tissue is available.

AB - Recent developments in genomics have resulted in the increased availability of gene profiles for early diagnosis and prognosis in breast cancer. A request from a Dutch woman to have her tumour tissue tested years after treatment confronted the Netherlands Cancer Institute (NKI) and its staff with legal, ethical, and practical questions regarding patients' rights in relation to residual tissue storage and its use for clinical purposes. Was her tissue still available? If so, could she demand that the test be carried out or her tissue be transferred to another hospital? As it became apparent that appropriate guidance was lacking in this area, we developed guidelines on the issue, with the involvement of relevant professionals and patient representatives within the framework of a Technology Assessment project.1Gene-expression profiling is an important development that is likely to predict the diagnosis and prognosis of malignant disease more accurately than existing clinicopathological parameters.2 Although gene-expression profiling is not yet routine, several tests are already applied in clinical practice. Additionally, the 70-gene signature (MammaPrint), which uses microarrays on fresh frozen tumour tissue, is being tested in a multicentre randomised trial (MINDACT).3 However, for such tests to be successful it is essential that sufficient tumour tissue is available.

KW - n/a OA procedure

U2 - 10.1016/S1470-2045(09)70318-3

DO - 10.1016/S1470-2045(09)70318-3

M3 - Article

SN - 1470-2045

VL - 11

SP - 9

EP - 11

JO - Lancet oncology

JF - Lancet oncology

IS - 1

ER -

Tumour tissue: Who is in control?

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this